MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy by Gaofeng Ni, Yuwei Sun, Hongling Jia, Zhikai Xiahou, Yumeng Li, Fu Zhao, Hongyan Zang

“…MAZ, identified as a key regulator, contributed to tumor progression, while the tumor microenvironment had a pivotal identity in immune evasion. …”
Get full text

Progression from Sustained BK Viruria to Sustained BK Viremia with Immunosuppression Reduction Is Not Associated with Changes in the Noncoding Control Region of the BK Virus Genome by Imran A. Memon, Bijal A. Parikh, Monique Gaudreault-Keener, Rebecca Skelton, Gregory A. Storch, Daniel C. Brennan

“…Our data support, at a genomic level, the effectiveness of reduction of immunosuppression for prevention of progression from viremia to BKVAN.…”
Get full text

Research progress in nursing of multiple myeloma with ostalgia (多发性骨髓瘤骨痛患者护理模式研究进展) by WANG Qiumei (王秋梅)

Get full text

Application progress of follow-up system in patients with malignant tumors (随访清单在恶性肿瘤患者中的应用现状) by LI Qianqian (李倩倩), LI li (李莉)

Get full text

Research progress on the use of turning apparatus in long-term bedridden patients (长期卧床患者使用翻身用具的研究进展) by WANG Tianxiu (王天秀), TAO Zhenyan (陶真妍), YU Ping (俞萍), YUAN Yuan (袁媛)

Subjects: Get full text

BRAF regulates circPSD3/miR-526b/RAP2A axis to hinder papillary thyroid carcinoma progression by Chuang Li, Xiaojuan Zhao, Jingge Zhao, Jing Zhao, Lemei An, Gang Wu

“…Furthermore, we found that overexpressing BRAF, which inhibits circPSD3, significantly hampers the progression of PTC.…”
Get full text

Research progress of systematic nursing intervention on cancer-related fatigue (癌因性疲乏系统性护理干预研究进展) by DOU Yan (窦燕), ZHANG Xiaoning (张晓宁), CUI Yufeng (崔玉枫), ZHANG Liying (张丽莹), LIU Chunzi (刘春梓)

Get full text

Research progress of acupoint application in the treatment of constipation in patients with diabetes mellitus (穴位贴敷治疗糖尿病便秘的研究进展) by LIU Bianyuan (刘变云), GUAN Yi (关漪), ZHANG Jingjin (张京津)

Get full text

Research progress of Management of acute skin failure in critically ill patients (重症患者急性皮肤衰竭管理的研究进展) by YUAN Yingying (袁迎迎), GAO Qian (高倩)

Get full text

Association of Autoimmune Thyroid Disease with Anti-GAD Antibody ELISA Test Positivity and Risk for Insulin Deficiency in Slowly Progressive Type 1 Diabetes by Masahito Katahira, Hidetada Ogata, Takahiro Ito, Tsutomu Miwata, Megumi Goto, Shizuka Nakamura, Hiromi Takashima

“…The presence of antiglutamic acid decarboxylase antibody (GADA) is required for the diagnosis of slowly progressive type 1 diabetes (SPT1D). We examined the factors influencing GADA determination by radioimmunoassay (GADA-RIA) and by enzyme-linked immunosorbent assay (GADA-ELISA). …”
Get full text

Staged Osteotome Sinus Floor Elevation for Progressive Site Development and Immediate Implant Placement in Severely Resorbed Alveolar Bone: A Case Report by Saad Al-Almaie

Get full text

Research progress on the cupping therapy along meridians in the treatment of constipation after stroke (循经拔罐治疗中风后便秘) by WANG Li (王丽), HUANG Chaoping (黄朝萍), WANG Fang (王芳), MA Xin (马欣), ZHANG Shuai (张帅), LI Yanmin (李艳敏), CHENG Jiangyan (程江艳), WANG Jing (王晶)

Get full text

Research progress and present situation of integrated medical and nursing ward rounds (医护一体化查房模式的研究进展及现状) by LI Qianqian (李倩倩), YE Yun (叶云)

Get full text

MSC-Derived Extracellular Vesicle-Delivered L-PGDS Inhibit Gastric Cancer Progression by Suppressing Cancer Cell Stemness and STAT3 Phosphorylation by Benshuai You, Can Jin, Jiaxin Zhang, Min Xu, Wenrong Xu, Zixuan Sun, Hui Qian

“…In this study, we aimed to explore whether MSC-EV-delivered L-PGDS (EVs-L-PGDS) could inhibit gastric cancer progression. EVs-L-PGDS were generated from MSCs transfected with adenovirus encoding L-PGDS. …”
Get full text

NEIL3 Mediates Lung Cancer Progression and Modulates PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target by Hongbo Huang, Qingwang Hua

“…In general, NEIL3 mediates NSCLC progression and affects sensitivity to immunotherapy and chemotherapy; therefore, it is a potential molecular target for treatment.…”
Get full text

The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease by James P. Hardwick, Byoung-Joon Song, Paul Rote, Charles Leahy, Yoon Kwang Lee, Alexandra Rudi Wolf, Danielle Diegisser, Victor Garcia

“…IntroductionMetabolic-dysfunction-associated steatosis liver disease (MASLD) is a progressive liver disease from simple steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. …”
Get full text

Association of accelerated phenotypic aging, genetic risk, and lifestyle with progression of type 2 diabetes: a prospective study using multi-state model by Lulu Pan, Yahang Liu, Chen Huang, Yifang Huang, Ruilang Lin, Kecheng Wei, Ye Yao, Guoyou Qin, Yongfu Yu

“…Conclusions PhenoAgeAccel was consistently associated with an increased risk of all transitions in T2D progression. It has the potential to be combined with genetic risk to identify early T2D incidence risk and may guide interventions throughout T2D progression while tracking their effectiveness.…”
Get full text

Bean, Frank D., Susan K. Brown y James D. Bachmeier, Parents without papers: The progress and pitfalls of Mexican-American integration by Eduardo Torre Cantalapiedra

Get full text

MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway by Zigui Chen, Chao Liu, Wei Zheng, Zhilong Li, Yuanhui Tang, Jun Peng, Changfeng Miao, Dandan Zheng, Ying Xia

“…The MYH9 gene is closely associated with tumour progression. However, the function and regulatory mechanism of MYH9 in tumour occurrence and development remain unclear. …”
Get full text

Risk Factors For Progression From Biochemical Leak to Clinically Relevant Postoperative Pancreatic Fistula After Pancreaticoduodenectomy.... by Mehmet Can Aydin, Oguzhan Ozsay, Kagan Karabulut, Recep Bircan, Fatih Atalay, Mehmet Batuhan Ors

“…While the progression rate was 58.3% in the group with PNI < 38, it was 10.6% with PNI ≥ 38. …”
Get full text